Medical scientists at Monash University have secured backing from French pharmaceutical giant Le Laboratoires Servier for development of a drug for Alzheimer’s disease.
The drug would target the protein insulin-regulated aminopeptidase (IRAP), and the hope is that it would both halt the development and alleviate symptoms of Alzheimer’s, the university said on 4 October.
The research is conducted by scientists at Monash University, St Vincent’s Institute of Medical Research and the Florey Institute of Neuroscience and Mental Health. Servier’s funding is aimed at determining exactly how IRAP inhibitors work to reduce amyloid plaque load in the brain.